Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus
- PMID: 17016482
- DOI: 10.1038/ncprheum0298
Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus
Abstract
Survival of patients with systemic lupus erythematosus (SLE) has improved over the past decade, thanks to improved treatment of the disease, which now results in fewer fatal complications. This improvement has allowed physicians to focus their attention on the prevention of organ damage caused by this chronic, inflammatory disease, and by the medications used to control the disease. Osteoporosis is common in SLE patients; risk factors for osteoporosis include prolonged use of glucocorticoids, cyclophosphamide and possibly gonadotropin-releasing-hormone agonists. In premenopausal women with SLE, inflammation or SLE-related medications can increase bone turnover, which eventually weakens bone architecture, then reduces bone strength and increases the risk of fracture. Prevention and treatment of osteoporosis in SLE patients should entail a multifaceted approach. Levels of calcium, vitamin D and homocysteine should be evaluated, and age-appropriate supplementation instituted. The bone loss that results from systemic inflammation should be treated by reduction of the inflammation with glucocorticoids, potent anti-inflammatory agents or antiresorptive agents. The efficacy of this therapy can be monitored using bone mineral density scans. This Review briefly discusses the pathophysiology of the localized and generalized osteoporosis and osteonecrosis in SLE patients and recommends therapies to both prevent and treat these unfortunate complications of this disease.
Similar articles
-
Osteoporosis in patients with systemic lupus erythematosus.Isr Med Assoc J. 2009 Aug;11(8):486-91. Isr Med Assoc J. 2009. PMID: 19891237 Review.
-
The management of secondary osteoporosis.Best Pract Res Clin Rheumatol. 2005 Dec;19(6):1021-37. doi: 10.1016/j.berh.2005.06.005. Best Pract Res Clin Rheumatol. 2005. PMID: 16301195 Review.
-
Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.Arthritis Rheum. 2007 Jun;56(6):1966-73. doi: 10.1002/art.22691. Arthritis Rheum. 2007. PMID: 17530722
-
Osteoporosis in systemic lupus erythematosus mechanisms.Rheum Dis Clin North Am. 2005 May;31(2):363-85, viii. doi: 10.1016/j.rdc.2005.01.004. Rheum Dis Clin North Am. 2005. PMID: 15922151 Review.
-
Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.J Rheumatol. 2008 Feb;35(2):230-6. Epub 2008 Jan 15. J Rheumatol. 2008. PMID: 18203323
Cited by
-
Low bone mineral density in Thai children with systemic lupus erythematosus: prevalence and risk factors.Asian Biomed (Res Rev News). 2021 Oct 29;15(5):245-250. doi: 10.2478/abm-2021-0030. eCollection 2021 Oct. Asian Biomed (Res Rev News). 2021. PMID: 37551322 Free PMC article.
-
Osteonecrosis of the distal tibia in systemic lupus erythematosus: A rare case report.Int J Surg Case Rep. 2020;77:126-128. doi: 10.1016/j.ijscr.2020.10.069. Epub 2020 Oct 28. Int J Surg Case Rep. 2020. PMID: 33160171 Free PMC article.
-
Magnesium and vitamin C supplementation attenuates steroid-associated osteonecrosis in a rat model.Biomaterials. 2020 Apr;238:119828. doi: 10.1016/j.biomaterials.2020.119828. Epub 2020 Jan 31. Biomaterials. 2020. PMID: 32045781 Free PMC article.
-
Risk factors for osteoporosis in male patients with chronic obstructive pulmonary disease in Taiwan.PeerJ. 2018 Jan 12;6:e4232. doi: 10.7717/peerj.4232. eCollection 2018. PeerJ. 2018. PMID: 29340241 Free PMC article.
-
MicroRNA-433-3p promotes osteoblast differentiation through targeting DKK1 expression.PLoS One. 2017 Jun 19;12(6):e0179860. doi: 10.1371/journal.pone.0179860. eCollection 2017. PLoS One. 2017. PMID: 28628652 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous